Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

M Wermke, E Felip, V Gambardella, Y Kuboki… - Future …, 2022 - Taylor & Francis
Poorly differentiated neuroendocrine carcinomas such as small-cell lung cancer (SCLC)
have poor survival and high relapse rates. DLL3 is found on these carcinomas and has …
被引用次数：38 相关文章

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

M Wermke, E Felip, V Gambardella, Y Kuboki… - 2022 - digitalcommons.wustl.edu
Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, Liu M, Studeny
M, Owonikoko TK. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3 …

Phase i trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

M Wermke, E Felip, V Gambardella, Y Kuboki… - Future …, 2022 - profiles.wustl.edu
Poorly differentiated neuroendocrine carcinomas such as small-cell lung cancer (SCLC)
have poor survival and high relapse rates. DLL3 is found on these carcinomas and has …

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

M Wermke, E Felip, V Gambardella… - Future oncology …, 2022 - pubmed.ncbi.nlm.nih.gov
Poorly differentiated neuroendocrine carcinomas such as small-cell lung cancer (SCLC)
have poor survival and high relapse rates. DLL3 is found on these carcinomas and has …